"This is the first off-label use of a drug tested in Alzheimer's patients in the last 10 years that has shown promise of benefit," said D. Larry Sparks, Ph.D., senior scientist and head of the Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute in Sun City, Ariz.
Animal and human studies have shown that elevated cholesterol is an important risk factor for Alzheimer's disease. Based on this research and Sparks's work for the past 20 years, he and colleagues in Bethesda, Md., New York City, Phoenix and Sun City, tested the effects of lowering cholesterol in people with mild-to-moderate Alzheimer's disease.
The Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT) was a double-blind, placebo-controlled pilot study that assessed whether lowering cholesterol with atorvastatin could stabilize or improve cognition in people with mild-to-moderate Alzheimer's. Doctors administered the statin drug in addition to the cholinesterase inhibitors the patients were already taking. Cholinesterase inhibitors are the only Food and Drug Administrationapproved therapy for mild-to-moderate Alzheimer's disease. The drugs inhibit the breakdown of acetylcholine, a transmitter that is decreased in Alzheimer's patients and thought to be related to mental decline.
The researchers evaluated 46 patients -- 25 on atorvastatin 80 mg and 21 on placebo -- for one year. The participants were, on average, 78-years-old with 14 years of education. One-third of the group was female. The patients were evaluated periodically for cognition, overall mental function and depression. Alzheimer's patients are known to have depression that usually gets worse as their Alzheimer
Contact: Darcy Spitz
American Heart Association